By: 30 December 2025
New study – Can gum cells cure knee arthritis?

 Scarcell Therapeutics, an innovator in cell therapies to treat chronic degenerative inflammatory diseases, recently announced the world’s first patients treated with its Allogenic Gingival Fibroblast (aGF) Therapy using gum cells from a human donor as part of its Phase Ib clinical trial studying the therapy in knee osteoarthritis (OA).

The first-in-human cases took place at Oxford University Hospitals, UK, and were led by Dr. Alex Shearman and Dr. Antony Palmer, orthopaedic surgeons and principal and co-investigator of the study, respectively, and Dr. Rajat Chowdhury, a musculoskeletal radiologist who performed the intraarticular cell injection of the knee.

OA is a complex, degenerative and incurable disease, involving multiple joint tissues and pain mechanisms. Scarcell’s patented aGF Therapy is uniquely designed to address all four of the major effects of OA – cartilage degeneration, joint inflammation, mobility and pain – in a single injection intended to be durable for up to one year. There is currently no commercial pharmaceutical or developmental cell therapy targeting all four effects.

“We are excited to lead research into this novel cell therapy for early OA, in an effort to address the unmet needs of many patients whose symptoms can be debilitating,” said Dr. Shearman. “The commencement of this trial is the result of a successful collaboration between orthopaedic surgeons, radiologists, specialist pharmacy and clinical research teams.”

Pre-aGF Therapy histology